Wellington Management Group LLP Buys 18,255 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Wellington Management Group LLP boosted its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 20.9% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 105,769 shares of the company’s stock after buying an additional 18,255 shares during the quarter. Wellington Management Group LLP owned 0.29% of iTeos Therapeutics worth $1,080,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Bank of New York Mellon Corp boosted its stake in shares of iTeos Therapeutics by 4.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 121,250 shares of the company’s stock worth $1,799,000 after purchasing an additional 5,409 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of iTeos Therapeutics by 35.9% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,998 shares of the company’s stock valued at $178,000 after buying an additional 3,172 shares during the period. Panagora Asset Management Inc. grew its stake in shares of iTeos Therapeutics by 8.9% during the second quarter. Panagora Asset Management Inc. now owns 131,553 shares of the company’s stock valued at $1,952,000 after buying an additional 10,787 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of iTeos Therapeutics by 8.5% in the second quarter. Rhumbline Advisers now owns 44,861 shares of the company’s stock worth $666,000 after buying an additional 3,513 shares during the period. Finally, Victory Capital Management Inc. lifted its stake in shares of iTeos Therapeutics by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 110,389 shares of the company’s stock worth $1,638,000 after acquiring an additional 16,629 shares during the last quarter. Institutional investors own 97.16% of the company’s stock.

Analyst Upgrades and Downgrades

ITOS has been the topic of several research analyst reports. Wells Fargo & Company cut their price objective on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a research report on Thursday. HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of iTeos Therapeutics in a report on Friday, December 13th. Finally, Wedbush reiterated an “outperform” rating and set a $25.00 price objective on shares of iTeos Therapeutics in a report on Thursday, December 12th.

Insider Activity

In related news, CFO Matthew Gall acquired 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was purchased at an average cost of $7.73 per share, for a total transaction of $38,650.00. Following the purchase, the chief financial officer now directly owns 65,429 shares of the company’s stock, valued at $505,766.17. This trade represents a 8.27 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 12.50% of the company’s stock.

iTeos Therapeutics Trading Down 0.6 %

ITOS opened at $7.22 on Friday. The company has a market capitalization of $263.78 million, a price-to-earnings ratio of -2.29 and a beta of 1.37. iTeos Therapeutics, Inc. has a 12-month low of $7.12 and a 12-month high of $18.75. The business’s fifty day simple moving average is $8.59 and its 200-day simple moving average is $12.71.

iTeos Therapeutics (NASDAQ:ITOS) last issued its earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.18) by $0.13. On average, equities research analysts predict that iTeos Therapeutics, Inc. will post -3.46 EPS for the current year.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.